ArticleScientific reports2026
Anticancer potential of radioactively activated zinc: mechanisms and therapeutic applications.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zinc (Zn), an essential trace element, has been shown to exhibit antiproliferative effects at high concentrations and to serve various functions in human health. Numerous studies have been undertaken to enhance the efficacy of zinc. In this study, the therapeutic efficacy of zinc in terms of activation by ionizing radiation was investigated, and whether this would increase its efficacy was determined. In this study, Zn-65 was detected by exposing zinc to X-rays using a novel approach. The present study investigates the biological effects of low-dose gamma irradiation with Zn-65 compared with zinc alone on MCF-7 breast cancer cells. Human umbilical cord endothelial cells (HUVECs) were used as a standard cell control. The study investigated the biological effects of Zn-65 (IR-Zn) on MCF-7 breast cancer cells, comparing them with non-irradiated zinc, using human umbilical cord endothelial cells (HUVECs) as a control. Cytotoxic activity, cell proliferation, apoptosis, cell cycle progression, and drug resistance profiles were evaluated. Our findings show that IR-Zn significantly enhances anticancer activity by inducing premature cell cycle arrest at the G0/G1 phase, promoting apoptosis, and suppressing ABCG2-mediated drug resistance mechanisms. This is the first study to demonstrate that low doses of gamma-emitting Zn-65 can elicit potent, selective cytotoxicity against cancer cells without severely damaging normal cells. The findings indicate that weak gamma-emitting Zn-65 may be a viable targeted and low-toxicity radiopharmaceutical candidate for prospective oncological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.